(CLX) The Clorox - NYSE
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 10.955m USD | Total Return: -20.8% in 12m
Avg Turnover: 254M
EPS Trend: 72.7%
Qual. Beats: 0
Rev. Trend: -75.4%
Qual. Beats: 0
Warnings
Altman Z'' 0.81 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
The Clorox Company (NYSE: CLX) is a U.S.-based manufacturer and marketer of consumer and professional products sold worldwide, organized into four reportable segments: Health and Wellness, Household, Lifestyle, and International. As a member of the Consumer Staples sector and the Household Products sub-industry, the company sells predominantly non-cyclical, everyday-use goods that tend to generate relatively stable, demand-resilient revenue.
Its brand portfolio spans cleaning and disinfecting products (Clorox, Pine-Sol, Tilex, Liquid-Plumr, Formula 409), professional cleaning solutions (CloroxPro, Clorox Healthcare), bags and wraps (Glad), cat litter (Fresh Step, Scoop Away), grilling (Kingsford), water filtration (Brita), natural personal care (Burts Bees), dressings and sauces (Hidden Valley), and a growing vitamins, minerals, and supplements line (Natural Vitality, RenewLife, NeoCell, Rainbow Light).
Clorox distributes its products through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet, and military stores, third-party and owned e-commerce channels, and distributors, supported by a direct sales force. The company was founded in 1913 and is headquartered in Oakland, California.
- Health and Wellness volumes normalize as pandemic demand fades
- Hidden Valley dressings face pressure from GLP-1 weight loss drugs
- Pricing power tested as private label competition grows in household
| Net Income: 756.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -8.63 > 1.0 |
| NWC/Revenue: -7.46% < 20% (prev -8.05%; Δ 0.59% < -1%) |
| CFO/TA 0.09 > 3% & CFO 576.0m > Net Income 756.0m |
| Net Debt (3.71b) to EBITDA (1.31b): 2.83 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.8m) vs 12m ago -1.84% < -2% |
| Gross Margin: 43.85% > 18% (prev 45.21%; Δ -1.36% > 0.5%) |
| Asset Turnover: 113.2% > 50% (prev 127.3%; Δ -14.18% > 0%) |
| Interest Coverage Ratio: 11.19 > 6 (EBIT TTM 1.08b / Interest Expense TTM 97.0m) |
| A: -0.08 (Total Current Assets 2.65b - Total Current Liabilities 3.15b) / Total Assets 6.44b |
| B: 0.03 (Retained Earnings 223.0m / Total Assets 6.44b) |
| C: 0.18 (EBIT TTM 1.08b / Avg Total Assets 5.97b) |
| D: -0.01 (Book Value of Equity -67.0m / Total Liabilities 6.34b) |
| Altman-Z'' = 0.81 = B |
| DSRI: 1.17 (Receivables 671.0m/597.0m, Revenue 6.76b/7.02b) |
| GMI: 1.03 (GM 45.21% / 43.85%) |
| AQI: 0.81 (AQ_t 0.34 / AQ_t-1 0.42) |
| SGI: 0.96 (Revenue 6.76b / 7.02b) |
| TATA: 0.03 (NI 756.0m - CFO 576.0m) / TA 6.44b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of June 24, 2026, the stock is trading at USD 92.64 with a total of 2,361,759 shares traded. Over the past week, the price has changed by -3.48%, over one month by -3.73%, over three months by -11.40% and over the past year by -20.84%.
Current recommended Stop Loss: 88.20 (which is 4.8% or 1.4 ATR below the current price).
The Clorox has received a consensus analysts rating of 2.89. Therefore, it is recommended to hold CLX.
- StrongBuy: 2
- Buy: 0
- Hold: 13
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 105.3 | 13.7% |
P/E Trailing = 14.7317
P/E Forward = 15.1976
P/S = 1.6206
P/B = 46.5805
P/EG = 2.1723
Revenue TTM = 6.76b USD
EBIT TTM = 1.08b USD
EBITDA TTM = 1.31b USD
Long Term Debt = 2.49b USD (from longTermDebt, last quarter)
Short Term Debt = 1.68b USD (from shortTermDebt, last quarter)
Debt = 4.89b USD (from shortLongTermDebtTotal, last quarter) + Leases 408.0m
Net Debt = 3.71b USD (calculated: Debt 4.89b - CCE 1.19b)
Enterprise Value = 14.7b USD (11.0b + Debt 4.89b - CCE 1.19b)
Interest Coverage Ratio = 11.19 (Ebit TTM 1.08b / Interest Expense TTM 97.0m)
EV/FCF = 38.59x (Enterprise Value 14.7b / FCF TTM 380.0m)
FCF Yield = 2.59% (FCF TTM 380.0m / Enterprise Value 14.7b)
FCF Margin = 5.62% (FCF TTM 380.0m / Revenue TTM 6.76b)
Net Margin = 11.18% (Net Income TTM 756.0m / Revenue TTM 6.76b)
Gross Margin = 43.85% ((Revenue TTM 6.76b - Cost of Revenue TTM 3.80b) / Revenue TTM)
Gross Margin QoQ = 43.23% (prev 43.16%)
Tobins Q-Ratio = 2.28 (Enterprise Value 14.7b / Total Assets 6.44b)
Interest Expense / Debt = 1.98% (Interest Expense 97.0m / Debt 4.89b)
Taxrate = 22.06% (218.0m / 988.0m)
NOPAT = 845.6m (EBIT 1.08b * (1 - 22.06%))
Current Ratio = 0.84 (Total Current Assets 2.65b / Total Current Liabilities 3.15b)
Debt / Equity = -73.04 (negative equity) (Debt 4.89b / totalStockholderEquity, last quarter -67.0m)
Debt / EBITDA = 2.83 (Net Debt 3.71b / EBITDA 1.31b)
Debt / FCF = 9.76 (Net Debt 3.71b / FCF TTM 380.0m)
Total Stockholder Equity = 147.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.65% (Net Income 756.0m / Total Assets 6.44b)
RoE = 514.3% (Net Income TTM 756.0m / Total Stockholder Equity 147.0m)
RoCE = 41.19% (EBIT 1.08b / Capital Employed (Equity 147.0m + L.T.Debt 2.49b))
RoIC = 18.31% (NOPAT 845.6m / Invested Capital 4.62b)
WACC = 4.42% (E(11.0b)/V(15.8b) * Re(5.71%) + D(4.89b)/V(15.8b) * Rd(1.98%) * (1-Tc(0.22)))
Discount Rate = 5.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.33 | Cagr: -1.02%
[DCF] Terminal Value 73.10% ; FCFF base≈548.4m ; Y1≈480.9m ; Y5≈388.6m
[DCF] Fair Price = 20.92 (EV 6.24b - Net Debt 3.71b = Equity 2.53b / Shares 120.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 72.74 | EPS CAGR: 12.76% | SUE: 0.38 | # QB: 0
Revenue Correlation: -75.36 | Revenue CAGR: -2.79% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-09-30): EPS=1.29 | Chg30d=-2.86% | Revisions=-67% | Analysts=11
EPS current Year (2026-06-30): EPS=5.54 | Chg30d=-0.48% | Revisions=N/A | GrowthEPS=-28.3% | GrowthRev=-5.9%
EPS next Year (2027-06-30): EPS=6.26 | Chg30d=-0.51% | Revisions=N/A | GrowthEPS=+13.1% | GrowthRev=+13.4%
[Analyst] Revisions Ratio: -67%